Lumexa Imaging (LMRI) investor relations material

Executive summary

• Q1 2026 consolidated revenue grew 3.1% year-over-year to $252.5 million, with system-wide revenue up 4.0%.

• Net income reached $1.7 million, reversing a net loss of $7.7 million in the prior year, driven by revenue growth and lower interest expense.

• Advanced modalities and strategic service lines drove growth, with PET up 23.1% and MRI up 8.2% year-over-year.

• Four new imaging centers opened, including two de novos and two acquisitions, supporting geographic expansion and JV partnerships.

• Outpatient imaging center footprint expanded to 189 centers in 13 states, with 103 consolidated and 86 joint venture centers.

Financial highlights

• Adjusted EBITDA was $51.2 million (20.3% margin), nearly flat year-over-year.

• GAAP EPS was $0.02; adjusted EPS was $0.18 per share.

• Net patient service revenue increased 2.6% to $188.99 million; management fee and other revenue rose 6.7% to $5.68 million.

• Cash and cash equivalents stood at $51.2 million at quarter-end.

• Net cash provided by operating activities was $2.9 million, compared to a use of $14.0 million in the prior year quarter.

Outlook and guidance

• Full-year 2026 revenue expected between $1.045 billion and $1.097 billion.

• Adjusted EBITDA guidance is $234 million–$242 million, with 7% growth at the midpoint excluding new public company costs.

• Adjusted EPS projected at $0.71–$0.77 per share.

• EBITDA and cash flow expected to ramp through the year, with 55% of Adjusted EBITDA in the second half.

• Targeting 8–10 de novo center additions in 2026.